Accéder au contenu
Merck

Prevention of orthopedic device-associated osteomyelitis using oxacillin-containing biomineral-binding liposomes.

Pharmaceutical research (2012-06-27)
Xin-Ming Liu, Yijia Zhang, Fu Chen, Irine Khutsishvili, Edward V Fehringer, Luis A Marky, Kenneth W Bayles, Dong Wang
RÉSUMÉ

To develop novel biomineral-binding liposomes (BBL) for the prevention of orthopedic implant associated osteomyelitis. A biomineral-binding lipid, alendronate-tri(ethyleneglycol)-cholesterol conjugate (ALN-TEG-Chol), was synthesized through Cu(I)-catalyzed Huisgen 1,3-dipolar cycloaddition (a versatile click reaction). Mixing with other excipients, the new lipid was used to develop BBL. Thermodynamic behavior was studied by differential scanning calorimetry (DSC). In vitro biomineral-binding potential and kinetics were evaluated on hydroxyapatite (HA, a widely used material for orthopedic implant devices) particles. Oxacillin was encapsulated into BBL and used for in vitro evaluation in preventing Staphylococcus aureus biofilm formation. DSC analysis showed that ALN-TEG-Chol could inhibit the phase transition of liposomes by reducing its cooperativity, yielding liposomes with thermodynamic stability similar to liposomes containing regular cholesterol. BBL showed fast and strong binding ability to HA. Oxacillin-loading BBL demonstrated significantly better preventive efficacy against bacteria colonization when challenged with S. aureus isolate, implying its potential in preventing orthopedic implant associated osteomyelitis. In this proof of concept study, novel BBL has been successfully developed and validated for reducing the frequency of implantable device-related infections.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Oxacillin sodium salt, 815-950 μg/mg (Oxacillin)
Supelco
Oxacilline sodium salt hydrate, VETRANAL®, analytical standard